Coya Therapeutics, Inc.

NASDAQ
COYA
paper.types.company
Rentabilité sur six mois: -14.11%
Rendement en dividendes: 0%
Secteur: Healthcare

5.6 $

-0.09 $ -1.58%
4.82 $
10.19 $

paper.min_max_per_year

Calendrier des promotions Coya Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.

plus de détails
The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2022-12-29
ISIN
US22407B1089
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0.0246 10
P/BV 0.0022 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -0.067 0
ROE -0.0751 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.7548 10
Debt/Ratio 0.000293 10
Debt/Equity 0.1205 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 59112.58 10
Rentabilité Ebitda, % 2378.04 10
Rentabilité EPS, % 1189.96 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 5.69 $ 0 $ 0 $ -1.58 % 0 % 0 %
common.calendar.number_days.7d 5.71 $ 0 $ 0 $ -1.93 % 0 % 0 %
common.calendar.number_days.30d 6.1 $ 5.6 $ 6.14 $ -8.2 % 0 % 0 %
common.calendar.number_days.90d 6.73 $ 4.93 $ 6.89 $ -16.79 % 0 % 0 %
common.calendar.number_days.180d 6.52 $ 4.93 $ 7.4 $ -14.11 % 0 % 0 %
common.calendar.number_days.1y 7.55 $ 4.82 $ 10.19 $ -25.83 % 0 % 0 %
common.calendar.number_days.3y 0 $ 3.3 $ 10.19 $ 0 % 0 % 0 %
common.calendar.number_days.5y 0 $ 3.3 $ 10.19 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 3.3 $ 10.19 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 5.31 $ 4.93 $ 7.4 $ 5.46 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Howard Berman Ph.D. Chairman & CEO 833.75k 1974 (51 année)
Mr. David S. Snyder CFO & COO 610.94k 1960 (65 années)
Dr. Fred Grossman D.O., FAPA President & Chief Medical Officer 610.63k 1962 (63 année)
Dr. Gregory MacMichael Ph.D. Chief Technical Officer N/A 1956 (69 années)
Dr. Michelle Frazier Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Aaron Thome Ph.D. Head of Neuroinflammation Platform N/A
Dr. Arun Swaminathan Ph.D. Chief Business Development Officer N/A

Informations sur l'entreprise

Adresse: United States, Houston. TX, 5850 San Felipe Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.coyatherapeutics.com